Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pro-Pharmaceuticals and UML enter into collaboration
Davanat is a new chemical entity of the galactomannan carbohydrate polymer family composed of mannose and galactose. Davanat, in combination with chemotherapies, is currently in Phase II trials
Davanat is a new chemical entity of the galactomannan carbohydrate polymer family composed of mannose and galactose. Davanat, in combination with chemotherapies, is currently in Phase II trials
The data showed that a single treatment with NX-1207 produced durable significant improvement. Statistical analysis of the controlled data showed that the results for NX-1207 reached statistical significance
Geron has received a $4 million milestone payment from Merck on account of the filing, and is eligible to receive additional development milestones as well as royalties on
In both studies, discontinuation rates due to adverse events (AEs) for Pristiq 50mg/day were similar to placebo. In the two studies, the rates of discontinuation due to AEs
The FDA has approved Teva’s abbreviated new drug application for oxcarbazepine tablets at 150mg, 300mg and 600mg milligrams. The drug is used to help control certain kinds of
Biomoda’s patented technology, a non-invasive cytology based assay, is designed for cancer screening of large populations at a reasonable cost. Current diagnostic methods for lung cancer, including CT
The Phase I trial was an open-label study conducted in 12 patients with advanced Parkinson’s disease at two clinical trial sites. It was previously reported that an average
The Diverge trial, a prospective, multi-center trial which enrolled 302 patients, is the largest study conducted to date with a drug-eluting stent specifically designed for treating bifurcation lesions.
Investors will also receive warrants to purchase 5,348,308 shares of AVI BioPharma’s common stock. The warrants have an exercise price of $2.45 per share and are exercisable at
The one-year (52-week), randomized, double-blind, placebo-controlled Phase II/III clinical trial will enroll approximately 200 patients and will be conducted at approximately 80 sites in North America, Europe, Latin